Abstract
Purpose
We sought to disentangle the effects of statins and other lipid-lowering drugs and the underlying dyslipidemia for which they are prescribed on breast cancer risk.
Methods
We conducted a case–control study within the linked Surveillance, Epidemiology, and End results (SEER)-Medicare data. Cases were women with invasive breast cancer aged 66 + years (N = 30,004) identified by SEER registries (years 2007–2011). Controls were women (N = 198,969) identified from a 5% random sample of Medicare recipients alive and breast cancer free in year of selection. Participants had a minimum of 13 months of Part A, Part B non-health maintenance organization Medicare and Part D Medicare coverage at least 13 months preceding cancer diagnosis/selection. Exposures were assessed until 12 months before diagnosis/control selection. Odds ratios (OR) and 99.9% confidence intervals (CI) were estimated using adjusted unconditional and multinomial logistic regression.
Results
ORs of invasive breast cancer associated with dyslipidemia, statins, and non-statin lipid-lowering drugs were 0.86 (99.9% CI 0.81–0.90), 1.07 (99.9% CI 1.03–1.13) and 1.03 (99.9% CI 0.95–1.11), respectively. Risk reductions with dyslipidemia were slightly greater when untreated than treated and did not vary much by time between dyslipidemia and breast cancer diagnosis. Whether treated or untreated, dyslipidemia was associated with greater reductions in risk for later stage than earlier stage breast cancer (p-heterogeneity < 0.0001).
Conclusions
Lipid-lowering drugs did not account for the lower breast cancer risk associated with dyslipidemia. Our data do not support using statins or other lipid-lowering drugs to prevent breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23:8606–8612
Undela K, Srikanth V, Bansal D (2012) Statin use and risk of breast cancer: a meta analysis of observational studies. Breast Cancer Res Treat 135:261–269
Borgquist S, Tamimi RM, Chen WY, Garber JE, Eliassen AH, Ahern TP (2016) Statin use and breast cancer risk in the Nurses’ Health Study. Cancer Epidemiol Biomark Prev 25:201–206
Fagherazzi G, Fabre A, Boutron-Ruault M-C, Clavel-Chapelon F (2010) Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. Eur J Cancer Prev 19:120–125
Desai P, Lehman A, Chlebowski RT, Kwan ML, Arun M, Manson JE, Lavasani S, Wasswertheil-Smoller S, Sarto GE, LeBoff M, Cauley J, Cote M, Beebe-Dimmer J, Jay A, Simon MS (2015) Statins and breast cancer stage and mortality in the Women’s Health Initiative. Cancer Causes Control 26:529–539
McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, Li CI (2013) Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age. Cancer Epidemiol Biomark Prev 22:1529–1537
Schairer C, Gadalla SM, Pfeiffer RM, Moore SC, Engels EA (2017) Diabetes, abnormal glucose, dyslipidemia, hypertension, and risk of inflammatory and other breast cancer. Cancer Epidemiol Biomark Prev 26:862–868
Santa-Maria CA, Stearns V (2013) Statins and breast cancer: future directions in chemoprevention. Curr Breast Cancer Rep 5:161–169
Gronich N, Rennert G (2013) Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol 10:625–642
O’Neill S, O’Driscoll L (2014) Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. https://doi.org/10.1111/obr.12229
Ni H, Liu H, Gao R (2015) Serum lipids and breast cancer risk: a meta-analysis of prospective cohort studies. PLoS ONE 10(11):e0142669. https://doi.org/10.1371/journal.pone.0142669
Touvier M, Fassier P, His M, Norat T, Chan DS, Blacher J, Hercberg S, Galan P, Druesne-Pecollo N, Latino-Martel P (2015) Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. Br J Nutr 114:347–357
Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ (2010) Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res 51:1546–1553
Savarese G, De Ferrari GM, Rosano GMC, Perrone-Filardi P (2015) Safety and efficacy of ezetimibe: a meta-analysis. Int J Cardiol 201:247–252
Bonovas S, Nikolopoulos GK, Bagos PG (2012) Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials. PLoS ONE 7(9):e45259. https://doi.org/10.1371/journal.pone.0045259
Ravnskov U, McCully KS, Rosch PJ (2012) The statin-low cholesterol-cancer conundrum. Q J Med 105:383–388
Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2005) Serum lipids, lipid lowering drugs, and the risk of breast cancer. Arch Intern Med 165:2264–2271
Kaye JA, Meier CR, Walker AM, Jick H (2002) Statin use, hyperlipidemia, and the risk of breast cancer. Br J Cancer 86:1436–1439
Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjørge T, Borena W, Hӓggstrӧm C, Engeland A, Nagel G, Almquist M, Selmer R, Tretli S, Concin H, Hallmans G, Jonsson H, Stattin P, Ulmer H (2013) Total serum cholesterol and cancer incidence in the Metabolic Syndrome and Cancer Project (Me-Can). PLoS ONE 8(1):e54242. https://doi.org/10.1371/journal.pone.0054242
Flink L, Underberg JA, Newman JD, Gianos E (2015) The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines? Curr Atheroscler Rep 17:494
Expert Panel of Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486–2497
Jewett PI, Gangnon RE, Trentham-Dietz A, Sprague BL (2014) Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010. Obstet Gynecol 124:727–733
Mehio-Sibai A, Feinleig M, Sibai TA, Armenian HK (2005) A positive and negative confounding variable? A simple teaching aid for clinicians and students. Ann Epidemiol 15:421–423
Wong ND, Chuang J, Wong K, Pham A, Neff D, Marrett E (2013) Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009–2010). Am J Cardiol 112:373–379
Acknowledgements
We would like to acknowledge the programming support of Winnie Ricker at Information Management Services, Inc.
Funding
This work was funded by the Intramural Research Program of the National Cancer Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Study complies with the current laws of the United States, the country within which it was performed.
Additional information
Data availability
The data that support the findings of this study are available from the National Cancer Institute, but restrictions apply to the availability of these data, which are under license for the study, and so are not publicly available.
Rights and permissions
About this article
Cite this article
Schairer, C., Freedman, D.M., Gadalla, S.M. et al. Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population. Breast Cancer Res Treat 169, 607–614 (2018). https://doi.org/10.1007/s10549-018-4680-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-018-4680-7